All News about ARS Pharmaceuticals, Inc. - Common Stock![]() ![]()
Analyst Ratings For ARS Pharmaceuticals
September 09, 2024
Via Benzinga
![]() ![]() ![]()
Looking Into ARS Pharmaceuticals's Recent Short Interest
August 19, 2024
Via Benzinga
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]()
ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024
February 22, 2024
Via GlobeNewswire
![]()
ARS Pharma Readies Data In Response To FDA's Rejection For Its EpiPen Alternative For Severe Allergic Reactions
February 20, 2024
Via Benzinga
Exposures
Product Safety
![]() ![]()
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|
ARS Pharmaceuticals, Inc. - Common Stock (NQ: SPRY )All News about ARS Pharmaceuticals, Inc. - Common Stock
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|